Smith & Nephew PLC
LSE:SN

Watchlist Manager
Smith & Nephew PLC Logo
Smith & Nephew PLC
LSE:SN
Watchlist
Price: 986 GBX 0.94% Market Closed
Market Cap: 8.6B GBX
Have any thoughts about
Smith & Nephew PLC?
Write Note

Gross Margin
Smith & Nephew PLC

69%
Current
70%
Average
47.1%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
69%
=
Gross Profit
3.9B
/
Revenue
5.6B

Gross Margin Across Competitors

Country UK
Market Cap 8.6B GBP
Gross Margin
69%
Country US
Market Cap 199B USD
Gross Margin
56%
Country US
Market Cap 191.3B USD
Gross Margin
67%
Country US
Market Cap 141.3B USD
Gross Margin
64%
Country US
Market Cap 134.2B USD
Gross Margin
69%
Country IE
Market Cap 104.6B USD
Gross Margin
65%
Country US
Market Cap 65.6B USD
Gross Margin
45%
Country DE
Market Cap 58.1B EUR
Gross Margin
38%
Country US
Market Cap 44.5B USD
Gross Margin
79%
Country CN
Market Cap 310B CNY
Gross Margin
64%
Country US
Market Cap 36.3B USD
Gross Margin
41%
No Stocks Found

Smith & Nephew PLC
Glance View

Market Cap
8.6B GBX
Industry
Health Care

Smith & Nephew PLC, a name synonymous with innovation in the medical technology sphere, began its journey in the late 19th century in the quaint city of Kingston upon Hull, England. This humble pharmaceutical shop evolved over time into a global leader in medical devices, driven by a commitment to improve people's quality of life through pioneering healthcare solutions. Today, the company stands as a key player in three core sectors: orthopedics, advanced wound management, and sports medicine. By focusing on these specialized areas, Smith & Nephew has set itself apart, effectively addressing the complex challenges faced by aging populations and a rising demand for minimally invasive treatments. Revenue streams pour in from their innovative products, which cater to both healthcare professionals and patients worldwide. In orthopedics, they make significant headway with implants and instruments used in hip and knee replacements, essential solutions in addressing joint deterioration and injury. Their advanced wound management division tackles issues from chronic wounds to burns, supplying dressings and delivery systems designed for optimal healing. Meanwhile, the sports medicine segment contributes by offering arthroscopy and enabling technologies, crucial for athletic injury prevention and recovery. By maintaining a strong pipeline of research and development initiatives, Smith & Nephew continues to enhance its offerings, pushing the envelope in medical technology and consequently fortifying its financial foundation.

SN Intrinsic Value
1 468.78 GBX
Undervaluation 33%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
69%
=
Gross Profit
3.9B
/
Revenue
5.6B
What is the Gross Margin of Smith & Nephew PLC?

Based on Smith & Nephew PLC's most recent financial statements, the company has Gross Margin of 69%.